US12516122B2ActiveUtilityA1

Anti-VISTA antibodies and fragments

78
Assignee: JANSSEN PHARMACEUTICA NVPriority: Dec 24, 2013Filed: Nov 18, 2021Granted: Jan 6, 2026
Est. expiryDec 24, 2033(~7.5 yrs left)· nominal 20-yr term from priority
Inventors:SNYDER LINDAPOWERS GORDON
G01N 33/57505G01N 33/5759G01N 33/5751C07K 2317/75C07K 2317/567C07K 2317/565C07K 2317/56C07K 2317/52C07K 2317/515C07K 2317/51C07K 16/3038C07K 16/3023C07K 16/3015A61K 45/06A61K 39/39558C12N 15/63C07K 2317/622C07K 2317/54C07K 2317/92C07K 2317/76C07K 2317/74C07K 2317/732C07K 2317/55C07K 2317/34C07K 2317/33C07K 2317/24C07K 2317/21A61K 2039/505A61K 39/395A61P 43/00A61P 37/02A61P 35/02A61P 35/00A61P 37/04C07K 16/2827G01N 33/57492G01N 33/5743G01N 33/57426
78
PatentIndex Score
0
Cited by
1,535
References
36
Claims

Abstract

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated or recombinant nucleic acid which encodes for an antibody or antibody fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA), which antibody:
 (i) comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and   (ii) comprises a VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO: 29 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30.   
     
     
         2 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises antibody or antibody fragment is a Fab, F(ab′)2, or scFv antibody fragment. 
     
     
         3 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment is a human or humanized antibody. 
     
     
         4 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable heavy chain polypeptide having a sequence at least 90% identical to SEQ ID NO:37. 
     
     
         5 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable heavy chain polypeptide having a sequence at least 95% identical to SEQ ID NO:37. 
     
     
         6 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable heavy chain polypeptide identical to SEQ ID NO:37. 
     
     
         7 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide having a sequence at least 90% identical to SEQ ID NO:44. 
     
     
         8 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide having a sequence at least 95% identical to SEQ ID NO:44. 
     
     
         9 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide identical to SEQ ID NO:44. 
     
     
         10 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide having a sequence at least 90% identical to SEQ ID NO:44 and a variable heavy chain polypeptide having a sequence at least 90% identical to SEQ ID NO:37. 
     
     
         11 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide having a sequence at least 95% identical to SEQ ID NO:44 and a variable heavy chain polypeptide having a sequence at least 95% identical to SEQ ID NO:37. 
     
     
         12 . The nucleic acid of  claim 1 , wherein the encoded antibody or antibody fragment comprises a variable light chain polypeptide having a sequence identical to SEQ ID NO:44 and a variable heavy chain polypeptide identical to SEQ ID NO:37. 
     
     
         13 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises a human constant region. 
     
     
         14 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises a human IgG1 constant domain. 
     
     
         15 . The nucleic acid of  claim 11 , wherein the encoded human constant domain comprises a mutation which impairs FcR binding or protease cleavage. 
     
     
         16 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises a human IgG1 heavy constant domain having the human IgG1 heavy constant domain sequence comprised in SEQ ID NO:55, SEQ ID NO:59, SEQ ID NO:60 or SEQ ID NO:61. 
     
     
         17 . The nucleic acid of  claim 1 , which comprises a human IgG1 light constant domain having the human IgG1 light constant domain sequence comprised in SEQ ID NO: 56. 
     
     
         18 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises a human IgG1 light constant domain having the human IgG1 light constant domain sequence comprised in SEQ ID NO:56. 
     
     
         19 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises the heavy chain polypeptide of SEQ ID NO:55, 59, 60 or 61 and the light chain polypeptide of SEQ ID NO: 56. 
     
     
         20 . The nucleic acid of  claim 1 , wherein the encoded antibody comprises the heavy chain polypeptide of SEQ ID NO: 61 and the light chain polypeptide of SEQ ID NO: 56. 
     
     
         21 . A vector comprising the nucleic acid of  claim 1 . 
     
     
         22 . A vector comprising the nucleic acid of  claim 12 . 
     
     
         23 . A vector comprising the nucleic acid of  claim 19 . 
     
     
         24 . A vector comprising the nucleic acid of  claim 20 . 
     
     
         25 . A recombinant cell which comprises a nucleic acid according to  claim 1 , operably linked to a promoter. 
     
     
         26 . A recombinant cell which comprises a nucleic acid according to  claim 12 , operably linked to a promoter. 
     
     
         27 . A recombinant cell which comprises a nucleic acid according to  claim 19 , operably linked to a promoter. 
     
     
         28 . A recombinant cell which comprises a nucleic acid according to  claim 20 , operably linked to a promoter. 
     
     
         29 . A recombinant cell according to  claim 25 , which comprises a mammalian cell. 
     
     
         30 . A recombinant cell according to  claim 28 , which comprises a mammalian cell. 
     
     
         31 . A recombinant cell according to  claim 25 , which comprises a CHO cell. 
     
     
         32 . A recombinant cell according to  claim 28 , which comprises a CHO cell. 
     
     
         33 . A method of producing an antibody or antibody fragment encoded by the nucleic acid of  claim 1  comprising culturing an isolated or recombinant cell comprising said nucleic acid operably linked to a promoter under conditions that result in the expression of said antibody or antibody fragment. 
     
     
         34 . A method of producing an antibody or antibody fragment encoded by the nucleic acid of  claim 12  comprising culturing an isolated or recombinant cell comprising said nucleic acid operably linked to a promoter under conditions that result in the expression of said antibody or antibody fragment. 
     
     
         35 . A method of producing an antibody or antibody fragment encoded by the nucleic acid of  claim 19  comprising culturing an isolated or recombinant cell comprising said nucleic acid operably linked to a promoter under conditions that result in the expression of said antibody or antibody fragment. 
     
     
         36 . A method of producing an antibody or antibody fragment encoded by the nucleic acid of  claim 20  comprising culturing an isolated or recombinant cell comprising said nucleic acid operably linked to a promoter under conditions that result in the expression of said antibody or antibody fragment.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.